<SEC-DOCUMENT>0001493152-24-031592.txt : 20240813
<SEC-HEADER>0001493152-24-031592.hdr.sgml : 20240813
<ACCEPTANCE-DATETIME>20240813160116
ACCESSION NUMBER:		0001493152-24-031592
CONFORMED SUBMISSION TYPE:	3/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240124
FILED AS OF DATE:		20240813
DATE AS OF CHANGE:		20240813

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Niklas Victoria Ninon Olivia
		CENTRAL INDEX KEY:			0002012250
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41934
		FILM NUMBER:		241201215

	MAIL ADDRESS:	
		STREET 1:		1651 NORTH BEVERLY DRIVE
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90210

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FibroBiologics, Inc.
		CENTRAL INDEX KEY:			0001958777
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				863329066
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		455 E. MEDICAL CENTER BLVD
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77598
		BUSINESS PHONE:		281-671-5150

	MAIL ADDRESS:	
		STREET 1:		455 E. MEDICAL CENTER BLVD SUITE 300
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77598

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FibroBiologics Inc.
		DATE OF NAME CHANGE:	20221216
</SEC-HEADER>
<DOCUMENT>
<TYPE>3/A
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3/A</documentType>

    <periodOfReport>2024-01-24</periodOfReport>

    <dateOfOriginalSubmission>2024-02-15</dateOfOriginalSubmission>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001958777</issuerCik>
        <issuerName>FibroBiologics, Inc.</issuerName>
        <issuerTradingSymbol>FBLG</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002012250</rptOwnerCik>
            <rptOwnerName>Niklas Victoria Ninon Olivia</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O FIBROBIOLOGICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>455 E. MEDICAL CENTER BLVD. SUITE 300</rptOwnerStreet2>
            <rptOwnerCity>HOUSTON</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>77598</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.28</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-02-16</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>185300</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.28</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-09-25</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>5000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">1/4 of the options vested on January 1, 2024, with the remainder vesting monthly over 36 months.</footnote>
        <footnote id="F2">All options vested on September 26, 2023, the one-year anniversary of the date of grant.</footnote>
    </footnotes>

    <remarks>This amendment is filed to include stock options in Table II that were inadvertently omitted in the original filing.</remarks>

    <ownerSignature>
        <signatureName>/s/ Mark Andersen, by Power of Attorney</signatureName>
        <signatureDate>2024-08-13</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
